Price History
Feb 9, 2026 — Aug 25, 2026Investment Snapshot
- P/E of 17.6 — reasonable valuation
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 220.0% with 21.2% net margin
Indivior Pharmaceuticals, Inc. (INDV) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $4.8 billion . Key value metrics: P/E ratio 17.6, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Indivior Pharmaceuticals, Inc. — Fundamental Analysis Summary
Indivior Pharmaceuticals, Inc. (INDV) trades at a trailing P/E of 17.6x — 30% below the Healthcare sector average of 25.2x.
On financial health, INDV shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 220.0% (sector average: -20.1%).
StockPik's composite Value Score for INDV is 71/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
INDV reports a high gross margin of 82.4% (sector average: 37.4%) and a strong operating margin of 32.3%.
INDV shows revenue growing at 4% year-over-year, with earnings growing at 10,400%.